ATE533056T1 - Verfahren zum auffinden von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren - Google Patents

Verfahren zum auffinden von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren

Info

Publication number
ATE533056T1
ATE533056T1 AT04027975T AT04027975T ATE533056T1 AT E533056 T1 ATE533056 T1 AT E533056T1 AT 04027975 T AT04027975 T AT 04027975T AT 04027975 T AT04027975 T AT 04027975T AT E533056 T1 ATE533056 T1 AT E533056T1
Authority
AT
Austria
Prior art keywords
vegf
cells
tumor
screening
methods
Prior art date
Application number
AT04027975T
Other languages
English (en)
Inventor
Marc Achen
Steven Stacker
Original Assignee
Vegenics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vegenics Pty Ltd filed Critical Vegenics Pty Ltd
Application granted granted Critical
Publication of ATE533056T1 publication Critical patent/ATE533056T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04027975T 2000-03-02 2001-03-02 Verfahren zum auffinden von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren ATE533056T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18636100P 2000-03-02 2000-03-02

Publications (1)

Publication Number Publication Date
ATE533056T1 true ATE533056T1 (de) 2011-11-15

Family

ID=22684635

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01913267T ATE284701T1 (de) 2000-03-02 2001-03-02 Methode zur behandlung von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren
AT04027975T ATE533056T1 (de) 2000-03-02 2001-03-02 Verfahren zum auffinden von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01913267T ATE284701T1 (de) 2000-03-02 2001-03-02 Methode zur behandlung von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren

Country Status (12)

Country Link
US (1) US20010038842A1 (de)
EP (1) EP1259248B1 (de)
JP (1) JP2003525248A (de)
KR (1) KR20020080461A (de)
AT (2) ATE284701T1 (de)
AU (1) AU4194601A (de)
CA (1) CA2401665A1 (de)
DE (1) DE60107815T2 (de)
ES (2) ES2377119T3 (de)
NZ (1) NZ520546A (de)
PT (1) PT1259248E (de)
WO (1) WO2001064235A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
EP1158985B1 (de) 1999-01-13 2011-12-28 Bayer HealthCare LLC GAMMA CARBOXYARYLSUBSTITUIERTE DIPHENYLHARNSTOFFVERBINDUNGEN ALS p38 KINASEHEMMER
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7611711B2 (en) * 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
CA2435503C (en) * 2001-01-19 2011-02-22 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
CN1555488A (zh) * 2001-07-12 2004-12-15 路德维格癌症研究院 淋巴管内皮细胞物质及方法
US20030113324A1 (en) * 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
US7794693B2 (en) * 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7666979B2 (en) * 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
AU2003278807A1 (en) 2002-03-01 2004-08-13 Bracco International B.V. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7985402B2 (en) * 2002-03-01 2011-07-26 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US20050250700A1 (en) * 2002-03-01 2005-11-10 Sato Aaron K KDR and VEGF/KDR binding peptides
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US20040248796A1 (en) * 2003-02-04 2004-12-09 Kari Alitalo VEGF-B and PDGF modulation of stem cells
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
ES2396368T3 (es) 2003-03-03 2013-02-21 Dyax Corporation Péptidos que se unen específicamente al receptor del HGF (CMET) y usos de los mismos
RU2248183C2 (ru) * 2003-03-11 2005-03-20 НИИ онкологии им. проф. Н.Н. Петрова Минздрава РФ Способ интраоперационной диагностики степени распространенности опухолевого процесса при колоректальном раке
EP1636585B2 (de) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl-harnstoffe mit kinasehemmender wirkung
EP1635860A2 (de) * 2003-06-12 2006-03-22 Ludwig Institute For Cancer Research Verwendung von vegf-c oder vegf-d in der wiederherstellende chirurgie
WO2005016963A2 (en) * 2003-06-12 2005-02-24 Ludwig Institute For Cancer Research Heparin binding veger-3 ligands
EP1663978B1 (de) 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
US20050239700A1 (en) * 2003-10-14 2005-10-27 Biogen Idec Inc. Treatment of cancer using antibodies to LRRC15
DE102007037008B4 (de) * 2007-08-06 2015-09-10 Siemens Aktiengesellschaft Diagnosesubstanz zur Anwendung in einem Verfahren zur Bestimmung der Aggressivität eines Prostatatumors
US9981018B2 (en) 2010-06-08 2018-05-29 The Cleveland Clinic Foundation Compositions and methods for modulating toll-like receptor 2 activation
WO2011156451A2 (en) * 2010-06-08 2011-12-15 The Cleveland Clinic Foundation Compositions and methods for modulating toll-like receptor 2 activation
RS60026B1 (sr) 2013-02-18 2020-04-30 Vegenics Pty Ltd Molekuli koji vezuju ligande i njihove upotrebe
CN103739710B (zh) * 2014-01-26 2015-12-09 中国人民解放军军事医学科学院基础医学研究所 一种抗vegf抗体及其应用
EP3541838A1 (de) * 2016-11-16 2019-09-25 Eli Lilly and Company Therapie für metastatisierendes kolorektalkarzinom unter verwendung von anti-vegfr-2- und anti-vegf-d-antikörpern

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002543A1 (fr) * 1996-07-15 1998-01-22 Chugai Research Institute For Molecular Medicine, Inc. Nouveaux facteurs analogues au vegf
EP1283268A3 (de) * 1996-08-23 2004-01-02 Ludwig Institute For Cancer Research Rekombinantes Vasculäres Endothelzellen Wachstumsfaktor D (VEGF-D)
CA2315977A1 (en) * 1997-12-24 1999-07-08 Ludwig Institute For Cancer Research Expression vectors and cell lines expressing vascular endothelial growth factor d, and method of treating melanomas
WO2000037025A2 (en) * 1998-12-21 2000-06-29 Ludwig Institute For Cancer Research Antibodies to truncated vegf-d and uses thereof
CZ20014444A3 (cs) * 1999-06-11 2002-05-15 Aventis Pharmaceuticals Products Inc. Protein Akt pro pouľití k indukci exprese VEGF

Also Published As

Publication number Publication date
WO2001064235A1 (en) 2001-09-07
NZ520546A (en) 2004-05-28
ATE284701T1 (de) 2005-01-15
ES2234818T3 (es) 2005-07-01
DE60107815D1 (de) 2005-01-20
EP1259248A4 (de) 2003-05-28
ES2377119T3 (es) 2012-03-22
KR20020080461A (ko) 2002-10-23
EP1259248A1 (de) 2002-11-27
PT1259248E (pt) 2005-04-29
EP1259248B1 (de) 2004-12-15
JP2003525248A (ja) 2003-08-26
AU4194601A (en) 2001-09-12
US20010038842A1 (en) 2001-11-08
CA2401665A1 (en) 2001-09-07
DE60107815T2 (de) 2005-12-08

Similar Documents

Publication Publication Date Title
ATE533056T1 (de) Verfahren zum auffinden von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren
Stohrer et al. Oncotic pressure in solid tumors is elevated
Lowy et al. Tenascin C in metastasis: A view from the invasive front
Bigatto et al. TNF-α promotes invasive growth through the MET signaling pathway
Comerota et al. A histological and functional description of the tissue causing chronic postthrombotic venous obstruction
WO2005065418A3 (en) Compositions and methods of use of targeting peptides for diagnosis and therapy
AU2003253986A8 (en) Gene expression profiling in biopsied tumor tissues
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
DE60126592D1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
DE60137264D1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
KR20140032346A (ko) 암의 치료/전이의 억제
WO2000055629A3 (en) Methods of diagnosing and treating breast cancer
Reis-Filho et al. Maspin expression in normal skin and usual cutaneous carcinomas
DE60309887D1 (de) Kombination von einem aromatasehemmer mit einem bisphosphonat
DE60044119D1 (de) Reagentien und verfahren zur erkennung von erkrankungen der brust
van Laarhoven et al. Effects of nicotinamide and carbogen in different murine colon carcinomas: immunohistochemical analysis of vascular architecture and microenvironmental parameters
Boueuf et al. Inhibition of adhesion breast cancer cells by anticoagulant drugs and cimetidine
DE60326871D1 (de) Verfahren zur dosierung von ngf zur in vitro diagnose von brustkrebs und therapeutische verwendung
Apanovich et al. Expression Profiles of Genes—Potential Therapy Targets—and Their Relationship to Survival in Renal Cell Carcinoma
Hsiao et al. Toll‐like receptor‐4 agonist inhibits motility and invasion of hepatoblastoma HepG2 cells in vitro
ATE239492T1 (de) Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen
WO2001055450A3 (en) AMPLIFIED GENES AT 17q23
JP7082804B2 (ja) Ｒａｇｅアプタマーを含む癌を治療するための医薬組成物
Wronski et al. 1273 Crispr/cas9 mediated knockout of ripk4 impairs spheroid formation and wnt/β-catenin signaling in melanoma cells
Casalou et al. 1272 p21Waf1/Cip1 is differentially expressed in epidermal versus follicular melanocytes and melanoma cells and is phenotypically regulated by UVB-mediated apoptosis